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Introduction
The measurement of glycosylated haemoglobin in blood
is vital for monitoring metabolic control in diabetics
[1-3]. The development of many different methods of
measurement (based on cation-exchange chromato-
graphy, electrophoresis, high performance liquid chro-
matography [HPLC], affinity chromatography, radio
and colorimetric immuno techniques) proves the impor-
tance of this assay [4]. Since the first HPLC method was
described [5] a number of modifications have been
reported (see the review by Ellis et al. [6]). Instruments
have been specially designed and commercialized (for
example by Helena Laboratories, Beaumont, Texas,
USA and Kyoto Daichi, Japan).
The evaluation of a recently commercialized semi-
automatic HPLC instrument, which performs analyses
on hemolysates from the original blood samples, is
reported.
Materials and methods
The instrument, commercialized by Bio-Rad Labora-
tories (Segrate, Milano, Italy), consists of a main unit,
containing the functional parts (autosampler, buffer
reservoir, pumps, column colorimeter, and a control
unit). A single piston pump is used with a step-gradient
valve system, by which the elution of the column is
performed with three phosphate buffers ofpH 5"7, 5"8 and
5"9 (unstated concentration) and increasing ionic
strength. The analytical column (4"0 x 150 mm) is filled
by a new cation exchanger (TSK gel, unstated composi-
tion). The column temperature is controlled at 23C by
forced ventilation in the column compartment.
The sample (5 !1 of venous blood, with mg/ml of
EDTA) is diluted automatically with ml ofhaemolysing
reagent (0"1% vol/vol polyoxyethylene-ether in borate
buffer); 20 1 of the haemolysate are used for analysis.
Spectrophotometric detection is performed at two
wavelengths (415 nm and 690nm) to ensure a stable
base-line. All the operations are controlled by a micro-
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processor and a built-in integrator performs data reduc-
tion. The final results are printed out together with a
chromatogram of the run. The order of elution of the
haemoglobin fractions is" HbAla, HbAb, HbF, HbAlc,
HbAo. Each run takes 8 min.
(a) HbAlc 4.0%
0
(b) HbAlc 6.8%
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Figure 1. Chromatograms of a normal (a) and a diabetic (b)
sample obtained after a standard run. X-axis: time (min);y-axis:
concentration, as a percentage of the total haemoglobin (upper
scale: 10%). The fractions separated are: (1)non-haemoglobin
peak; (2) HbAla; (3) HbAIb; (4) HbF; (5) HbAc; and (6)
HbAo.A. Carpinelli et al. Evaluation of a new semi-automated HPI,C method for haemoglobins
The reference method used for the evaluation was the
Bio-Rad Laboratories microchromatographic method for
HbAlc performed at 23 C, as previously described [7].
The alkali denaturation method, modified according to
Molden [8], was used for HbF identification.
Blood samples used were collected by the Clinical
Chemistry Laboratory and the Clinical Medicine Division
(H. S. Raffaele, Milano, Italy). A Coulter S-Plus IV
(Kontron, Switzerland) was used to measure the haemato-
logical parameters. Some ethylene glycol stabilized
haemolysates were also prepared, according to a previ-
ously reported procedure [9], and used within two months.
Analytical imprecision was measured using blood sam-
ples and a lyophylised control material (Lypocheck
Hemoglobin Alc, from Bio-Rad Laboratories).
Results and discussion
Figure shows the chromatograms obtained after the
analysis of a normal (a) and a diabetic sample (b). The
analyser separates four or five haemoglobin fractions
depending on the HbF level (see later). The amount of
each species and the order of elution are closely similar to
those obtained by liquid chromatography with the
Bio-Rex 70, under the conditions reported by Wacks et al.
[10]. In order to test whether or not the amount of
haemoglobin loaded to the column would interfere with
analytical accuracy, as reported for the microchromato-
graphic methods 11 ], samples with different haematocrit
values and similar glycosylated haemoglobin levels were
analysed. The samples were prepared by diluting packed
red blood cells with different volumes of their own
plasma. The results obtained showed that, for haematoc-
rits between 22% and 75%, no appreciable effect is
produced on the results of analysis, i.e. no haematocrit-
effect can be detected.
The analytical precision, within and between runs, was
also analysed; the results obtained are reported in table 1.
In order to evaluate the within-series precision the
analyses were repeated eight times on a blood sample
from a normal subject, 10 times on blood from a diabetic
patient and 17 times on the control lyophylised material.
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Figure 2. Comparison with the reference method in the HbAlc
determination. The equation derived from the linear regression
analysis is:y 0"991 x -0"32; n 43; r 0"985, P < 0"001.
The dashed line correspond to the theoretical regression equation:y
1:000 x + 0"00.
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Figure 3. Comparison between the present method and the alkali
denaturation method, for the measurement ofHbF (y 0.41 x
-0"12; n 29; r 0"634; P < 0"001). Dashed line as in
figure 2.
Table 1. Precision. For ecich set of data the mean and the standard deviation (as a percentage of the total haemoglobin) are reported.
Coefficients ofvariation are shown in parentheses.
Sample n
Within-run
Normal 8
Diabetic l0
LyphocheckA 17
HbAa HbAlb HbF HbAlc
0.3 + 0.1 (0.0) 0.5 + 0.1 (10.0) 0.5 __+ 0.1 (7"2) 4.1 0.1 (1.1)
0.4 + 0.1 (13.0) 0.6 + 0.1 (5.2) 6.8 +_. 0.1 (1.0)
1.1 0.1 (4.2) 1.9 0.1 (3.0) 7.3 +__ 0.1 (1.5)
Between-run
Low-level ethylene glycol
haemolysate
High-level ethylene glycol
haemolysate
0.3 _+ 0.1 (13.7) 0.6 + 0.0 (0.0) 4.6 + 0.1 (2.5)
0.3 0.1 (8.1) 0"6 .1 (4.0) 7.3 +__ 0.1 (1.4)
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NAME ":, TIME. QREQ
AIA 8.4 2.3 34.92
IB . 2.9 68.5
IC 5.1 4.8 512.87
.5 ?
HBIqIC 5 % HB! 6 ’’
NAME
AIAB
IC
P4
" TIME AREA
13.1 2.5 1032.81
8.7 4.2 o0.44
4.4 4.9 345.36
Bl.8 5.8 6453.16
HBIIC 8.7% HBII 13.8%
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NAME % TIME
AIAB 0.1 2.3
F 85 ’9
AIC 8.3 3.9
8 2.5 4.8
P5 56. 5.7
P6 48.7 6.
8.72
78.83
46.37
428.53
9558.11
6923.71
HBIC 8.3.’.: HBq! 8.3.’..:
ui
NME X TIME
lqlFI B 3,3
18 1.8 2.9
IC 1.2 3.8
0 4.7 4,.8
P5 92,9 5,7
18%
RE
13.3
121.65
143.68
568.87
11884.7!
HBIC I.,... ’’’ HBFII 2.4%
NME % TIME RE
lB 8, 2. .67
F 3.1 2.9 381.6
AIC 2.5 3 "
8 3.2 4.8 313.86
P5 91 8 5 7 887 ,i;
HB] C 2. 5% HBA .."
18%
’8%
Figure 4. Chromatograms obtainedfrom the analysis ofhaemoly-
satesfrom subjects sufferingfrom different haemoglobinopathies
(a) normal control; (b) HbS ([36glu-- val) trait; (c) HbE ([326
glu lys) trait; (d) HbJ Paris (od2 ala asp) trait; and (e)
Hb Lepore trait (6 --> fusion). The concentrations of mutant
haemoglobins in each sample, determined by cellulose acetate
electrophoresis at pH 8"4, with respect to the total haemoglobin
concentration were: HbS 38%; HbE 33%; HbJ Paris
24%; and Hb Lepore 12%.
The between-run precision was tested over a period ofone
month, analysing two ethylene glycol stabilized haemoly-
sates nine times (every third day). Each daily measure-
ment was performed in duplicate.
The accuracy in the measurement of HbAlc was evalu-
ated by measuring this fraction in 41 blood samples with
both the present method and the reference method. The
data obtained are shown in figure 2.A. Carpinelli et al. Evaluation of a new semi-automated HPLC method for haemoglobins
The accuracy ofHbF measurement was determined on a
limited number of samples, the data being reported in
figure 3. It can be seen that the accuracy is not
satisfactory. Further methodological improvements must
be introduced to resolve this quantitatively minor frac-
tion which has great clinical relevance for the characteri-
zation of the [3-thalassemia syndromes.
Interference by abnormal haemoglobins was investigated
by analysing haemolysates from subjects suffering from
various haemoglobinopathies, which had previously been
characterized. Figure 4 shows that in all the specimens
analysed, the instrument produced an abnormal chro-
matogram; if an abnormal haemoglobin was present it
showed as an anomalous peak, indicated as P4, P5 or P6.
In the case with HbS (see figure 4[b]), the HbAo peak is
split into two fractions, the last one (P6) probably
corresponding to the HbS present in the sample. There is
good correlation between the amount of this fraction
(40"7%) and the HbS concentration in the sample (38%)
determined separately by cellulose acetate electrophore-
sis (CAE) at pH 8"4. The position of the peak suggests
also that the fraction may have an electrophoretic
mobility slower than that ofHbAo, as is to be expected for
HbS.
A somewhat similar comparison holds for the sample
showing the HbJ Paris trait (see figure 4[d]). This
haemoglobin variant has greater mobility than HbA0 on
CAE, and it is therefore expected to be eluted among the
first fractions. The chromatogram shows an elevation in
the HbAa and HbAb fractions, which are eluted
together. The concentration of these fractions (13"1%) is
too high even for a sample from a diabetic person, and
indicates the presence of interference. The concentration
found using this analysis is significantly lower than that
measured by CAE.
In the case of the Hb Lepore trait (see figure 4[e]), a
variant with electrophoretic mobility close to that ofHbF,
an abnormal chromatographic pattern is shown, but
detection of the type of the variant from the chromato-
gram is very uncertain.
Characterization is also impossible in the case of the
sample showing the HbE trait (see figure 4[c]). This
mutant has a very low electrophoretic mobility at pH 8"4
(similar to that ofHbA2) and elution is therefore expected
after HbAo. In this case the HbAo peak is not split, as
with the HbS trait sample, but the chromatogram is
abnormal at the boundary between the HbAo peak
(elution time 5"3 min). The final peak shows a small
shoulder on its right-hand side.
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Figure 5. The effect of incubation with 4.0 g/l glucose (a) and
9.0 g/l NaCl (b) on the assay of glycosylated haemoglobins.
Incubations were performed at 37C using erythrocytesfrom two
normal and two diabetic subjects. The reagents used were:
(0 (D) Glycopack haemolysing reagent 30’ at room tempera-
ture; (A / Glycopack haemolysing reagent 30’ at 37C;
(-- ) haemolysing reagent without borate buffer, 10’ at
25C.
From our experience we can therefore conclude that the
instrument is more sensitive to the presence ofabnormal
haemoglobins in the sample than are the minicolumns
which are normally used. The operator should be alerted
by the appearance of anomalous peaks but further
electrophoretic investigations need to be performed from
full diagnosis. The estimation ofthe true HbAc levels can
be attempted by a careful observation of the chromato-
gram, knowing that, under standard conditions, the
elution time for HbAlc is about 4.8 min.
The influence of so-called ’labile glycosylated haemoglo-
bin’ fractions on this method was also examined.
Erythrocytes were incubated separately with glucose
(4"0 g/l) and with saline solution (9"0 g/1 NaC1) at 37 C,
for up to 24 h. No significant increase in the HbAc levels
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of three blood samples (one from normal and two from
diabetic subjects) after 24h of incubation with the
glucose solution was detected (see figure 5[a]). Similarly,
no significant decrease in the initial HbAlc levels was
found in two blood samples (one normal and one
diabetic) incubated with saline for 24 h (see figure 5[b]).
Furthermore, in order to evaluate the presence of the
labile fractions in the incubated erythrocytes, the same
samples were analysed for HbAlc levels, using an
haemolysing reagent without borate (the same haemolys-
ing reagent previously commercialized Bio-Rad Labora-
tories forassays of HbA1). This kind of reagent does not
eliminate the aldimine forms during the haemolysis step.
In fact, the results ofthese determinations (see the dashed
lines in figure 5) showed an increase in the HbA levels
after the glucose incubations, and a significant decrease
in the HbAc concentrations after the incubations with
saline.
It can therefore be concluded that the method described
here is insensitive to the presence of the ’labile fractions’,
which are reported to interfere strongly with many
chromatographic methods.
In this evaluation no experiment was performed to test
the effect of temperature on the analytical resolution of
the minor haemoglobin fractions. Reports in the literat-
ure indicate that this effect is evident with all the
procedures based on ion-exchange chromatography and,
to a smaller extent, with those using affinity chromato-
graphy [12]. It is assumed that a thermoregulated
column compartment within the apparatus will eliminate
any interference from temperature variations on the
chromatographic pattern.
In summary, it would appear that this system could be of
significant value for the measurement of glycosylated
haemoglobin. It combines good precision and accuracy
with practicality for speed, technical skill requirements
and safety. The system can also be useful in evaluating
samples from subjects suffering from some haemoglobi-
nopathies where diagnosis may frequently be missed by
conventional chromatographic techniques, normally
used to measure glycosylated haemoglobin levels.
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SEMINAR
22 and 23 October 1986: Minnetonka, Minnesota, USA
The Seminar, entitled ’Crossflow Membrane Filtration’, will be oriented toward engineers, managers or persons
responsible for water treatment, pollution control or process engineering. Topics covered include the use of
cross-flow RO, UF and MF membranes for industrial water treatment, medical/pharmaceutical water
treatment, waste water reclamation and the recovery ofmetal salts, oils and other organics from waste or process
streams. The seminar will cover the fundamentals of reverse osmosis, ultrafiltration and microfiltration, total
system design considerations, storage and distribution of water, and the ’zero discharge’ approach to pollution
control. Hands-on equipment operation, installation, start-up and repair is included.
For more information contact Laura Wedding, OSMO Membrane Systems Division, OSMONICS, INC. 5951 Clearwater
Drive, Minnetonka, MN 55343, USA. Tel.: 612 933 2277.
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